Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC)

被引：23
|
作者：
Zhu, Andrew X. [1 ,2 ]
Guan, Yinghui [3 ]
Abbas, Alexander R. [3 ]
Koeppen, Hartmut [3 ]
Lu, Shan [3 ]
Hsu, Chih-Hung [4 ]
Lee, Kyung-Hun [5 ]
Lee, Michael S. [6 ]
He, Aiwu Ruth [7 ]
Mahipal, Amit [8 ]
Ding, Beiying [3 ]
Spahn, Jessica [3 ]
Verret, Wendy [3 ]
Ryoo, Baek-Yeol [9 ]
Wang, Yulei [3 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Jiahui Int Canc Ctr, Boston, MA USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Natl Taiwan Univ Hosp, Taipei, Taiwan
[5] Seoul Natl Univ, Seoul, South Korea
[6] UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[7] Georgetown Univ, Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[8] Mayo Clin, Rochester, MN USA
[9] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-CT044
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT044
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
    Zhu, Andrew X.
    Abbas, Alexander R.
    de Galarreta, Marina Ruiz
    Guan, Yinghui
    Lu, Shan
    Koeppen, Hartmut
    Zhang, Wenjun
    Hsu, Chih-Hung
    He, Aiwu Ruth
    Ryoo, Baek-Yeol
    Yau, Thomas
    Kaseb, Ahmed O.
    Burgoyne, Adam M.
    Dayyani, Farshid
    Spahn, Jessica
    Verret, Wendy
    Finn, Richard S.
    Toh, Han Chong
    Lujambio, Amaia
    Wang, Yulei
    NATURE MEDICINE, 2022, 28 (08) : 1599 - +
  • [2] Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
    Andrew X. Zhu
    Alexander R. Abbas
    Marina Ruiz de Galarreta
    Yinghui Guan
    Shan Lu
    Hartmut Koeppen
    Wenjun Zhang
    Chih-Hung Hsu
    Aiwu Ruth He
    Baek-Yeol Ryoo
    Thomas Yau
    Ahmed O. Kaseb
    Adam M. Burgoyne
    Farshid Dayyani
    Jessica Spahn
    Wendy Verret
    Richard S. Finn
    Han Chong Toh
    Amaia Lujambio
    Yulei Wang
    Nature Medicine, 2022, 28 : 1599 - 1611
  • [3] Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma
    Muto, Hisanori
    Kuzuya, Teiji
    Kawabe, Naoto
    Ohno, Eizaburo
    Funasaka, Kohei
    Nagasaka, Mitsuo
    Nakagawa, Yoshihito
    Miyahara, Ryoji
    Shibata, Tomoyuki
    Hashimoto, Senju
    Katano, Yoshiaki
    Hirooka, Yoshiki
    ANTICANCER RESEARCH, 2023, 43 (10) : 4673 - 4682
  • [4] Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma
    Tsilimigras, Diamantis I.
    Moris, Dimitrios
    JOURNAL OF BUON, 2021, 26 (02): : 637 - 638
  • [5] Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
    Ahmed, Faiza
    Onwumeh-Okwundu, Jennifer
    Yukselen, Zeynep
    Endaya Coronel, Maria-Kassandra
    Zaidi, Madiha
    Guntipalli, Prathima
    Garimella, Vamsi
    Gudapati, Sravya
    Mezidor, Marc Darlene
    Andrews, Kim
    Mouchli, Mohamad
    Shahini, Endrit
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 13 (11) : 1813 - 1832
  • [6] Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
    Faiza Ahmed
    Jennifer Onwumeh-Okwundu
    Zeynep Yukselen
    Maria-Kassandra Endaya Coronel
    Madiha Zaidi
    Prathima Guntipalli
    Vamsi Garimella
    Sravya Gudapati
    Marc Darlene Mezidor
    Kim Andrews
    Mohamad Mouchli
    Endrit Shahini
    World Journal of Gastrointestinal Oncology, 2021, 13 (11) : 1813 - 1832
  • [7] PREDICTING RESPONSE TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA
    Cappuyns, Sarah
    Pique-Gili, Marta
    Esteban-Fabro, Roger
    Philips, Gino
    Pinyol, Roser
    Vandecaveye, Vincent
    Abril-Fornaguera, Jordi
    Haber, Philipp
    Verslype, Chris
    Van Cutsem, Eric
    Lambrechts, Diether
    Villanueva, Augusto
    Dekervel, Jeroen
    Llovet, Josep M.
    HEPATOLOGY, 2023, 78 : S1871 - S1872
  • [8] Result of atezolizumab plus bevacizumab for advanced or metastatic hepatocellular carcinoma in Vietnamese patients
    Hoang, H. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S88 - S88
  • [9] Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab
    Ha, Yeonjung
    Kim, Jee Hyun
    Cheon, Jaekyung
    Jeon, Gyeong Sik
    Kim, Chan
    Chon, Hong Jae
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (09) : 2421 - +
  • [10] Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
    Cheon, Jaekyung
    Yoo, Changhoon
    Hong, Jung Yong
    Kim, Han Sang
    Lee, Dae-Won
    Lee, Myung Ah
    Kim, Jin Won
    Kim, Ilhwan
    Oh, Sang-Bo
    Hwang, Jun-Eul
    Chon, Hong Jae
    Lim, Ho Yeong
    LIVER INTERNATIONAL, 2022, 42 (03) : 674 - 681
12345